Skip to main content
Fig. 8 | The Journal of Headache and Pain

Fig. 8

From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Fig. 8

Change in WPAI domain scores in A) participants aged ≥60 years and B) overall population. WPAI, Work Productivity and Activity Impairment; LSM, least-squares mean; LSMD, least-squares mean difference; SE, standard error. Data shown are the LSM changes from baseline in WPAI domain scores during 12 weeks of double-blind treatment. aP < 0.005 vs placebo. bP < 0.05 vs placebo. cP < 0.01 vs placebo. dP ≤ 0.001 vs placebo. eP < 0.0001 vs placebo. fP < 0.0005 vs placebo

Back to article page